Asymmetric Cerebellar Ataxia and Limbic Encephalitis as a Presenting Feature of Primary Sjogrens Syndrome
J Neurol 254:1609-1611, Collison,K. and Rees,J., 2007
Neuromyelitis Optica Spectrum Disorder
NEJM 387:631-639, Wingerchuk, D.M. & Lucchinetti, C.F., 2022
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Autoimmune Encephalitides: A Broadening Field of Treatable Conditions
Neurologist 22:1-13, Kalman, B., 2017
Clinicopathologic Conference, Paraneoplastic Stiff Person Syndrome with Limbic Encephalitis with Anti-Amphiphysin Antibodies with Metastatic Carcinoma of Breast
NEJM 367:851-861, Case 27-2012, 2012
Diagnosis and Management of the Antiphospholipid Syndrome
BMJ 340:1125-1132, Cohen,D., et al, 2010
Voltage-gated Potassium Channel-associated Limbic Encepahlitis in the West of Scotland:Case Reports and Literature Review
Scott Med J 54:27-31, Reid,J.M.,et al, 2009
Stiff-Person Syndrome
The Neurologist 10:131-137, Murinson,B.B., 2004
Management of Multiple Sclerosis
NEJM 337:1604-1611, Rudick,R.A.,et al, 1997
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
Clinicopathological Conference, Glutamic Acid Decarborylase 65 Autoantibody-Associated Stiff-Person Syndrome
NEJM 390:1712-1719, Case 14-2024, 2024
Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024
An 8-Year-Old with Acute Onset Ataxia
Neurol 99:305-310, McLaren, J.R.,et al, 2022
Vaccine-Induced Thrombocytopenia with Severe Headache
NEJM 385:doi:10.1056/NEJMc2112974, Salih, F.,et al, 2021
An 82-year-old man with Worsening Gait
Neurol 89:e246-e252, Chew, S.,et al, 2017
International Consensus Guidance for Management of Myasthenia Gravis
Neurol 87:419-425, Sanders, D.B.,et al, 2016
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Clinicopathologic Conference, Acute Infectious Mononucleosis due to Epstein-Barr Virus Infection, Complicated by Acute Otitis Media and Postinfectious Cerebellitis
NEJM 369:1253-1261, Case 30-2013, 2013
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Autoimmune Epilepsy
Arch Neurol 69:582-593,565, Quek, A.M.L.,et al, 2012
Guillain-Barre Syndrome
NEJM 366:2294-2304, Yuki, N. & Hartung, H.P., 2012
Immunotherapy-Responsive Chorea as the Presenting Feature of LGI1-Antibody Encephalitis
Neurol 79:195-196, Tofaris,G.K.,et al, 2012
Morvan Syndrome: Clinical and Serological Observations in 29 Cases
Ann Neurol 72:241-255, Irani, S.R.,et al, 2012
Adult-Onset Opsoclonus-Myoclonus Syndrome
Arch Neurol 69:1598-1607, Klaas, J.,et al, 2012
Clinical Reasoning: A 34-year-old man with recurrent limb weakness
Neurol 77:e68-e72, Karam, C.,et al, 2011
Comparative Analysis of Therapeutic Options Used for Myasthenia Gravis
Ann Neurol 68:797-805, Mandawat,A.,et al, 2010
Relapse Management in Multiple Sclerosis
The Neurologist 15:1-5, Thrower,B.W., 2009
Guillain-Barre Syndrome
BMJ 337:227-231, Winer,J.B., 2008
Multifocal Motor Neuropathy: The Diagnostic Spectrum and Response to Treatment
Neurol 69:1680-1687, Slee,M.,et al, 2007
Guillain-Barre Syndrome
Lancet 366:1653-1666, Hughes,R.C. &Comblath,D.R., 2005
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Management of Myasthenia Gravis
Semin Neurol 24:41-48, Saperstein,D.S. &Barohn,R.J., 2004
Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis: Randomised Placebo-Controlled Trial
Lancet 364:1149-1156, Hommes,O.R.,et al, 2004
Potassium Channel Antibody-Associated Encephalopathy: A Potentially Immunotherapy-Responsive Form of Limbic Encepahlitis
Brain 127:701-712, Vincent,A.,et al, 2004
Clinicopath Conf., Chronic Inflammatory Demyelinating Polyneuropathy
NEJM 348:735-743, Case 6-2003, 2003
Practice Parameter:Immunotherapy for Guillain-Barre Syndrome, Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurol 61:736-740, Hughes,R.A.C.,et al, 2003
Treatment of Autoimmune Myasthenia Gravis
Neurol 61:1652-1661, Richman,D.P. & Agius,M.A., 2003
Disease Modifying Therapies in Multiple Sclerosis
Neurol 58:169-178, Goodin,D.S.,et al, 2002
Intravenous Immunoglobulin in Neurological Disease: A specialist Review
JNNP 72:440-448, Wiles,C.M.,et al, 2002
Systematic Review of Immunomodulatory Drugs for the Treatment of People with Multiple Sclerosis: Is There Good Quality Evidence on Effectiveness and Cost?
JNNP 70:574-579, Bryan,J.,et al, 2001
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Intravenous Immunoglobulin in the Treatment of Autoimmune Neuromuscular Diseases:Present Status and Practical Therapeutic Guidelines
Muscle & Nerve 22:1479-1497, Dalakas,M.C., 1999
Intravenous Immune Globulin Therapy for Neurologic Diseases
Ann Int Med 126:721-730, Dalakas,M.C., 1997
Treatment of Inflammatory Myopathies
Muscle & Nerve 20:651-664997., Mastaglia,F.L.,et al, 1997
Treatment of Acquired Myasthenia Gravis
Neurol 48 (Suppl 5) :S46-S51997., Massey,J.M., 1997
Complications of Intravenous Gammaglobulin in Neuromuscular and other Disease
Muscle & Nerve 19:388-391996., Bertorini,T.E.,et al, 1996
Treatment of Opsoclonus-Myoclonus with High-Dose Intravenous Immunoglobulin
Neurol 46:583-584, Pless,M.,et al, 1996
Intravenous Immunoglobulin Treatment of Neurological Disease
JNNP 60:359-361, Otten,A.,et al, 1996